An interdisciplinary team from Memorial Sloan-Kettering Cancer Center has shown how antibiotics can disrupt the normal, healthy balance of microorganisms in the gastrointestinal tract.
Memorial Sloan-Kettering Cancer Center researchers have published new findings that may help explain why brain tumors called glioblastomas are so resistant to treatment.
A new center at the Sloan-Kettering Institute is exploring the potential of embryonic stem cells and human adult cells to produce regenerative treatments and provide insights into cancer.
The US Food and Drug Administration announced today that the drug ipilimumab (brand name Yervoy) has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.
Memorial Sloan-Kettering Cancer Center and Gerstner Sloan-Kettering President Craig Thompson and his wife opened their home for a reception for prospective Gerstner Sloan-Kettering students invited for admissions interviews.
Researchers at Memorial Sloan-Kettering Cancer Center’s Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.
